Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia

Elderly Patients Clinical Trial

— QUALI  

Official title:

Description the Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia : Prospective Descriptive Non-comparative Cohort ( QUALI Cohort)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03743961
• Other study ID #: 2018-0801
• Secondary ID: 2018-A02315-50
• Status: Terminated
• Start date: November 21, 2018
• Est. completion date: July 2, 2020

Study information

• Verified date: July 2020
• Source: Institut de Cancérologie de la Loire
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to describe the impact of : Geriatric intervention contribution on quality of life of elderly patients receiving systemic treatments for metastatic neoplasia

Description:

Elderly cancer incidence increases exponentially with advancing age. However, elderly patients are largely underrepresented in cancer treatment trials. The geriatric population presents particular physical, mental, psychological or social specificities that may condition the prognosis especially for patients with metastatic neoplasia. Recently, the measurement of quality of life (QoL) in aging population is being recognized as an important part of clinical decision. It is therefore essential to set up prospective studies to evaluate the impact of oncogeriatric practices on the quality of life of elderly patients with metastatic neoplasia. The main objective of this prospective study is to describe the contribution of geriatric intervention on quality of life for for elderly (> 75 years) with metastatic solid cancer receiving systemic treatment during the first 6 months of their therapeutic management.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 28
• Est. completion date: July 2, 2020
• Est. primary completion date: July 2, 2020
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Patient with solid metastatic neoplasia

• 75 years old or more

• Men or women

• ECOG between 0 and 3

• Patient receiving systemic antineoplasic treatment (chemotherapy, hormonotherapy, immunotherapy, targeted therapy)

Exclusion Criteria:

• ECOG 4

• Localized cancer

• Patients already included in a study witch could modify quality of life

• Patient unable to give their consent

Related Conditions & MeSH terms

• Elderly Patients
• Metastatic Neoplasia
• Neoplasms
• Systemic Treatment

Intervention

Other:
• geriatric intervention
Geriatric intervention

Locations

Country	Name	City	State
France	Institut de Cancérologie Lucien Neuwirth	Saint-Priest-en-Jarez

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Cancérologie de la Loire

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of quality of life	Level of quality of life will be measured with the QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions)	6 months
Primary	Level of quality of life	Level of quality of life will be measured with the QoL Q30 (Quality Qf Life with 30 Questions)	6 months
Secondary	number of hospitalizations	number of hospitalizations will be reported	6 months
Secondary	Duration of hospitalizations	Duration of hospitalizations will be reported in hours	6 months
Secondary	Number of toxicities ( grade 3 and 4)	Number of toxicities (grade 3 and 4) will be reported according to the CTCAE v4.0 (Common Terminology Criteria for Adverse Events)	6 months